Latest news with #GPR40
National Post
3 days ago
- Health
- National Post
Innospera Pharma Appoints Dr. Glenn Crater as Chief Medical Officer to Support Advancement of ING-006 Toward the Clinic
Article content MONTREAL — Innospera Pharma Inc. ('Innospera'), a private, near-clinical-stage biotechnology company advancing differentiated small molecule modulators of GPR84 and GPR40 to treat inflammatory and metabolic diseases, today announced the appointment of Dr. Glenn Crater, MD, FCCP as Chief Medical Officer (CMO). Glenn will start immediately as a fractional CMO, with the commitment to joining full time as the Company's lead compound reaches the clinic. Article content Dr. Crater brings to Innospera over 25 years of clinical, regulatory, and leadership experience in pulmonary medicine and drug development. A board-certified pulmonologist, Dr. Crater has played pivotal roles in advancing respiratory drug candidates, with particular expertise in Idiopathic Pulmonary Fibrosis (IPF) — the initial target indication for Innospera's lead compound, ING-006, which is poised to enter clinical development in the near future. Article content 'We are thrilled to welcome Glenn to Innospera at this critical moment in our growth,' said François Ravenelle, PhD, Chief Executive Officer of Innospera. 'Having worked closely with Glenn at Inversago Pharma, I've witnessed first-hand his commitment to scientific rigor, clinical excellence, and patient impact. His deep understanding of IPF and drug development will be invaluable as we initiate clinical studies for ING-006 and build a pipeline of novel GPR84/GPR40 modulators.' Article content Prior to joining Innospera, Dr. Crater served as Chief Medical Officer at multiple biotechnology companies and held senior medical leadership positions across both private and public firms, contributing to successful regulatory submissions and clinical programs in respiratory and fibrotic diseases. Article content 'I'm excited to reunite with François and the team at Innospera,' said Dr. Crater. 'ING-006 represents a promising new approach to modulating inflammation and fibrosis via GPCR lipid signaling. I look forward to advancing this program in the clinic and working to deliver transformative therapies for patients living with IPF and related diseases.' Article content About Innospera Pharma Article content Article content Article content
National Post
05-05-2025
- Business
- National Post
François Ravenelle, PhD Appointed President and CEO of Innospera Pharma to Lead Next Phase of Growth
Article content Article content MONTREAL — Innospera Pharma Inc. ('Innospera'), a private, near-clinical-stage biotechnology company focused on developing small-molecule modulators of GPR84 and GPR40 to address a broad range of inflammatory and metabolic diseases with high unmet medical needs, today announced the appointment of François Ravenelle, PhD, as President and Chief Executive Officer, effective immediately. Article content 'With strong preclinical evidence and the potential to address chronic conditions such as idiopathic pulmonary fibrosis, Innospera is uniquely positioned to make a meaningful impact in the field of inflammatory-related conditions.' – François Ravenelle Dr. Ravenelle is an accomplished biotech leader with over two decades of experience in pharmaceutical R&D and executive management. He most recently served as President and CEO of Inversago Pharma, a clinical-stage company developing therapies based on peripheral CB1 receptor blockade to treat metabolic and fibrotic diseases. Under his leadership, Inversago raised more than $100M, and was acquired by Novo Nordisk for up to approximately $1 billion USD. Article content 'I'm thrilled to join Innospera at this pivotal stage, as the company moves toward clinical development with a lead asset that shows strong potential for an exceptional balance of safety and efficacy in targeting inflammatory and metabolic pathways,' said Dr. Ravenelle. 'With strong preclinical evidence and the potential to address chronic conditions such as idiopathic pulmonary fibrosis, Innospera is uniquely positioned to make a meaningful impact in the field of inflammatory-related conditions. I'm excited to contribute to the company's next phase of growth.' Article content Pierre Laurin, Executive Chairman of the Board, founder and former CEO, commented: 'François' appointment comes at the perfect time following the completion of our seed financing round. His proven leadership and strategic vision will be invaluable as we prepare for clinical development and beyond. Investissement Québec, Seido Capital, and Anges Québec worked synergistically together to support Innospera's vision, based on the strong potential of our lead assets. We are privileged to work in one of the best life science clusters in North America, where innovation is recognized by quality investors, acting together as catalysts for promising endeavours like ours.' Article content About Long-term Inflammation Article content Systemic inflammation (inflammaging), increases as a consequence of aging contributing to age-related morbidities. Persistent activation of fibrotic pathways and organ dysfunction is markedly more frequent in the elderly (fibroaging). Elderly individuals with chronic disorders tend to develop inflammaging, a condition associated with elevated levels of blood inflammatory markers and increased susceptibility to chronic disease progression. Chronic, low-grade inflammation is a crucial contributor to various age-related pathologies and natural processes in aging tissue, including the lung, kidney, heart, liver, nervous and the musculoskeletal system. Article content Article content Article content Article content Article content Contacts Article content Article content
Business Wire
05-05-2025
- Business
- Business Wire
François Ravenelle, PhD Appointed President and CEO of Innospera Pharma to Lead Next Phase of Growth
MONTREAL--(BUSINESS WIRE)-- Innospera Pharma Inc. ('Innospera'), a private, near-clinical-stage biotechnology company focused on developing small-molecule modulators of GPR84 and GPR40 to address a broad range of inflammatory and metabolic diseases with high unmet medical needs, today announced the appointment of François Ravenelle, PhD, as President and Chief Executive Officer, effective immediately. "With strong preclinical evidence and the potential to address chronic conditions such as idiopathic pulmonary fibrosis, Innospera is uniquely positioned to make a meaningful impact in the field of inflammatory-related conditions." - François Ravenelle Share Dr. Ravenelle is an accomplished biotech leader with over two decades of experience in pharmaceutical R&D and executive management. He most recently served as President and CEO of Inversago Pharma, a clinical-stage company developing therapies based on peripheral CB1 receptor blockade to treat metabolic and fibrotic diseases. Under his leadership, Inversago raised more than $100M, and was acquired by Novo Nordisk for up to approximately $1 billion USD. 'I'm thrilled to join Innospera at this pivotal stage, as the company moves toward clinical development with a lead asset that shows strong potential for an exceptional balance of safety and efficacy in targeting inflammatory and metabolic pathways,' said Dr. Ravenelle. 'With strong preclinical evidence and the potential to address chronic conditions such as idiopathic pulmonary fibrosis, Innospera is uniquely positioned to make a meaningful impact in the field of inflammatory-related conditions. I'm excited to contribute to the company's next phase of growth.' Pierre Laurin, Executive Chairman of the Board, founder and former CEO, commented: 'François' appointment comes at the perfect time following the completion of our seed financing round. His proven leadership and strategic vision will be invaluable as we prepare for clinical development and beyond. Investissement Québec, Seido Capital, and Anges Québec worked synergistically together to support Innospera's vision, based on the strong potential of our lead assets. We are privileged to work in one of the best life science clusters in North America, where innovation is recognized by quality investors, acting together as catalysts for promising endeavours like ours.' About Long-term Inflammation Systemic inflammation (inflammaging), increases as a consequence of aging contributing to age-related morbidities. Persistent activation of fibrotic pathways and organ dysfunction is markedly more frequent in the elderly (fibroaging). Elderly individuals with chronic disorders tend to develop inflammaging, a condition associated with elevated levels of blood inflammatory markers and increased susceptibility to chronic disease progression. Chronic, low-grade inflammation is a crucial contributor to various age-related pathologies and natural processes in aging tissue, including the lung, kidney, heart, liver, nervous and the musculoskeletal system. About Innospera Innospera is a privately-owned biotech company near clinical stage, developing small molecule modulators of 7-transmembrane receptors involved in a broad range of chronic and fibrotic conditions. The company's lead drug candidates target key G-protein coupled receptors (GPCR) involved in fibroaging and inflammaging, including idiopathic pulmonary fibrosis (IPF), a condition with dire short-term prognosis. Innospera also develops multiple other modulators with promising potency in other medical conditions with pressing unmet needs. For more information, visit
